Exploring the anti-influenza virus activity of novel triptolide derivatives targeting nucleoproteins

Bioorg Chem. 2022 Dec:129:106118. doi: 10.1016/j.bioorg.2022.106118. Epub 2022 Aug 31.

Abstract

Triptolide (TP) is a major active compound derived from the traditional Chinese medicine Tripterygium wilfordii. TP has been reported to inhibit the infection of HIV and a few other viruses. However, the antiviral spectrum and the underlying mechanisms of TP are incompletely defined. TP derivatives were designed, synthesized, and evaluated for anti-influenza activity against the influenza A virus in this study. All of them exhibited activities against oseltamivir sensitive influenza A/WSN/33 virus (H1N1) and oseltamivir resistant influenza A/PR/8/33 virus (H1N1) with low cytotoxicity in vitro. In our present study, TP derivatives probably suppressed influenza virus replication through inhibiting ribonucleoprotein complex nucleus export of influenza A virus by binding with viral nucleoprotein. Moreover, TP derivatives downregulated influenza A virus-induced macrophage cytokine storm in a dose-dependent manner, through inhibiting nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) and NOD-like receptor protein 3 (NLRP3) inflammasome signaling. Taken together, TP derivatives suppressed influenza A virus replication by directly targeting NP and regulating innate immune responses induced by influenza A virus infection, which suggested that TP derivatives might be prospective candidates for potent antivirals.

Keywords: Antiviral; Inflammation; Influenza A virus; Nucleoprotein; Triptolide derivatives.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / chemistry
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza A virus*
  • Influenza, Human* / drug therapy
  • Nucleoproteins / chemistry
  • Nucleoproteins / metabolism
  • Oseltamivir / metabolism

Substances

  • Nucleoproteins
  • triptolide
  • Oseltamivir
  • Antiviral Agents